Management of metabolic complications of therapy.
Considerable efforts are underway to define effective strategies for the treatment of metabolic complications of HIV therapy. Clearly these problems dominate the overall approach to treatment of HIV infection in the settings where antiretroviral agents are accessible. While progress has been made it has been slow, and accompanied by disappointments. There are currently no effective treatments for lipoatrophy, and while treatments for dyslipidemia have been described, in most cases the improvement is incomplete. While these efforts must continue it is hoped that a new focus on prevention of metabolic complications will begin to emerge in the year ahead.